Drugs / Anti-human Thymocyte Immunoglobulin
Anti-human Thymocyte Immunoglobulin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06984536 | May → Jul 2025 overdue | acute leukemia, myelodysplastic syndrome | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-human Thymocyte Immunoglobulin | “Anti-human Thymocyte Immunoglobulin (ATG) based” NCT06984536 ↗ |
| Known as | ATG | “Anti-human Thymocyte Immunoglobulin (ATG) based” NCT06984536 ↗ |
| Known as | r-ATG | “r-ATG (total 7.5mg/kg ,from days -5 to -2)” NCT06984536 ↗ |
| Modality | Protein / enzyme biologic | “Anti-human Thymocyte Immunoglobulin (ATG) based” NCT06984536 ↗ |